According to incomplete statistics, as of September 23rd, 49 companies had announced their first three-quarter results.
, the proportion of companies reporting positive results increased by 13, with 26.53 per cent, while the proportion of companies with pre-performance declined by 8 and 7 reported losses.
According to the author's combing found that, in terms of industry classification, mainly concentrated in software and information technology services, special equipment manufacturing, pharmaceutical manufacturing and other industries, of which, the pharmaceutical manufacturing industry has issued the first three quarters of the earnings forecast of 11 companies, the first three quarters of net profit pre-increased by 4 companies, the proportion of companies reported a happy 36.36 percent, pre-loss 4, early warning 2, pre-level 1.
among the pharmaceutical companies with positive results, with the median expected net profit growth statistics, a total of 1 company's net profit growth in the range of 50% to 100%, 2 growth in the range of 0 to 50%, in addition, the happy but not yet disclosed the growth rate of 1.
Oriental Bio: Oriental Bio, which expects net profit growth of more than 50% by the end of the third quarter, expects net profit to increase by more than 50% year-on-year, based on the company's final disclosure of the third quarter 2020 report, according to the rules of listing on the Board.
first half of the year, the company's net profit increased more than 14 times year-on-year.
data show that Oriental Bio is a company specializing in in-body diagnostic product research and development, production and sales, a comprehensive coverage of antigen antibody biological raw materials, in-body diagnostic reagents, in-body diagnostic instruments of the entire industrial chain layout, the current main in-body diagnostic reagent products, the future focus on the development of molecular diagnosis, biological raw materials, diagnostic instruments and liquid biochips and other products.
: Expected net profit growth of 41.43 percent to 49.29 percent was followed by pre-tech bio, which forecast net profit of $270 million to $285 million in the first three quarters, up 41.43 percent from a year earlier to 49.29 percent.
company made the above forecast for the following reasons: mainly due to the accelerated resumption of production in the downstream pig breeding industry and the rising demand for vaccines for pigs.
public information shows that pre-technology is a focus on animal biological products research and development, production, sales and animal epidemic prevention technical services of biopharmaceutical enterprises, the main products are pig vaccines and poultry vaccines.
Yuandong Bio: Expected net profit growth of 21.14 percent to 36.94 percent Yuandong Bio forecast net profit of 115 million to 130 million yuan in the first three quarters of 2020, up 21.14 percent year-on-year to 36.94 percent.
made the forecast based on increased sales of Fumaric acid pesolor tablets and increased revenue from ibuprofen injections, and the launch of new products based on cosy tablets and injection parrishib sodium.
Public information shows that Yuandong Bio is a research and development innovation-driven high-tech enterprises, chemical raw materials and chemical preparations research and development, production and sales of the main business, has injection, freeze-dried powder needles, tablets, capsules and other dosage forms and chemical raw materials production capacity.
: The net profit is expected to increase significantly from the same period last year, and the sales volume of related products such as nucleic acid testing reagents in the first half of this year will increase significantly in the first half of this year, resulting in a significant increase in the company's overall operating performance.
its 2020 half-year net profit has significantly exceeded the level of the first three quarters of 2019, so the cumulative net profit for the first three quarters of 2020 is expected to increase significantly from a year earlier.
said that because of testing demand, policies, as well as the company's overseas business promotion effect is uncertain and unpredictable, at the same time, the market competition intensified, if the company can not win by quality, brand, price and other factors, market share will be affected to a certain extent;
above factors can cause the company's performance fluctuations to a certain extent, so the company can not predict the January-September 2020 net profit compared with the same period last year specific growth.